Barinthus Biotherapeutics

Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.

Founded 2016

Oxford, United Kingdom 34 employees Acquired Total: $146.66M Biotechnology, Health and Wellness +1

General Information

Company Name Barinthus Biotherapeutics

Founded Year 2016

Location

Oxford, United Kingdom

Founders / Decision Makers

Employees 34

Industries Biotechnology, Health and Wellness, Pharmaceutical

Funding Stage Acquired

Business Model B2B, B2D

Revenue Model Licensing, Product Sales

Offices as of Sep 2026

‏Harwell‏، ‏Oxfordshire‏ ‏OX11 0DF‏، ‏GB‏, ‏Harwell‏، ‏Oxfordshire‏ ‏OX11 0DF‏، ‏GB‏ ‏Germantown‏، ‏Maryland‏ ‏20874‏، ‏US‏, ‏Germantown‏، ‏Maryland‏ ‏20874‏، ‏US‏

Social

BounceWatch is an independent company data service, not affiliated with Barinthus Biotherapeutics. To contact Barinthus Biotherapeutics, visit barinthusbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Barinthus Biotherapeutics compare?

A PDF of Barinthus Biotherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Barinthus Biotherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Barinthus Biotherapeutics

Barinthus Biotherapeutics, founded in 2016, is a United Kingdom-based clinical-stage biopharmaceutical company that is innovating in the realms of Biotechnology, Health and Wellness, and Pharmaceutical industries. The company specializes in developing novel T-cell immunotherapeutic candidates aimed specifically at tackling chronic infectious diseases, autoimmunity, and cancer.

Centered around its slogan, "Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.", the company leverages four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI. Their pipeline includes five diverse product candidates such as VTP-300 and VTP-1000, showcasing their extensive expertise and focus on impactful medical challenges.

In its recent acquisition on 01 September 2025, Clywedog Therapeutics invested in Barinthus, positioning the company as a strong candidate for investors seeking growth opportunities in the biopharmaceutical industry.

Business keywords: T-cell immunotherapeutics, Chronic infectious diseases, Autoimmunity, Cancer treatment, ChAdOx technology, MVA boost vector, SNAP-TI platform, SNAP-CI platform, CD8+ T cells, Chronic HBV treatment, Celiac disease treatment, Prostate cancer treatment, Viral vaccine development, Biopharmaceutical innovation, Immunotherapeutic pipeline

Services & Products

Development of antigen-specific immunotherapies

Phase 1b/2 clinical trials

Pipeline management for autoimmune diseases and chronic viral infections

Biopharmaceutical research and development

Target Customers

Patients with autoimmune and inflammatory conditions Patients with chronic viral infections Healthcare providers Oncologists

Funding Rounds & Investors (7)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Acquisition	Undisclosed	1	Clywedog Therapeutics	01 Sep 2025
Series B	$110.50M	-		01 Apr 2021
Grant	£160.00K	1	UK Research and Innovation	01 Aug 2020
Late VC	£6.00M	2	Korea Investment Partners, GeneMatrix	01 Dec 2018
Series A	£20.00M	5	GV, Oxford Science Enterprises +3	01 Jan 2018
Early VC	£10.00M	1	Oxford Science Enterprises	01 Nov 2016
Spinout	Undisclosed	2	The University of Oxford, Oxford University Innovation	01 Jan 2016

Latest News

View All

EU-Startups Podcast | Episode 96: Julia Hawkins, General Partner at LocalGlobe and Latitude

Eu-startups Nov 21, 2024

Barinthus Biotherapeutics Alternatives & Competitors

View All Alternatives

Barinthus Biotherapeutics vs

Jasper Therapeutics United States

Jasper is a biotechnology company focused on targeting mast cells and stem cells to treat chronic di...

IPO

41 employees

Biotechnology, Health Care

Compare Barinthus Biotherapeutics vs Jasper Therapeutics

Barinthus Biotherapeutics vs

Imcyse SA Belgium

Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune diseases

Series B

17 employees

Biotechnology, Health and Wellness

Compare Barinthus Biotherapeutics vs Imcyse SA

Barinthus Biotherapeutics vs

Cabaletta Bio United States

Engineered T cell therapies designed for the treatment of patients with autoimmune diseases

IPO

191 employees

Biotechnology, Pharmaceutical

Compare Barinthus Biotherapeutics vs Cabaletta Bio

View all alternatives

FAQ About Barinthus Biotherapeutics

Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.

Barinthus Biotherapeutics was founded in 2016.

Barinthus Biotherapeutics is headquartered in Oxford, United Kingdom. As of Sep 2026, it also has offices in ‏Harwell‏، ‏Oxfordshire‏ ‏OX11 0DF‏، ‏GB‏, ‏Harwell‏، ‏Oxfordshire‏ ‏OX11 0DF‏، ‏GB‏ and ‏Germantown‏، ‏Maryland‏ ‏20874‏، ‏US‏, ‏Germantown‏، ‏Maryland‏ ‏20874‏، ‏US‏.

Barinthus Biotherapeutics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on T-cell immunotherapeutics, Chronic infectious diseases, Autoimmunity and Cancer treatment. Its customers include Patients with autoimmune and inflammatory conditions, Patients with chronic viral infections and Healthcare providers.

Barinthus Biotherapeutics has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.

Barinthus Biotherapeutics has approximately 34 employees.

Barinthus Biotherapeutics has completed 7 funding rounds, raising a total of $146.66M. The latest funding stage is Acquired.

Barinthus Biotherapeutics offers: Development of antigen-specific immunotherapies, Phase 1b/2 clinical trials, Pipeline management for autoimmune diseases and chronic viral infections, Biopharmaceutical research and development.

Top alternatives and competitors to Barinthus Biotherapeutics include Jasper Therapeutics, Imcyse SA, Cabaletta Bio, Via Nova Therapeutics, Transgene. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Barinthus Biotherapeutics and Jasper Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Barinthus Biotherapeutics, https://bouncewatch.com/company/vaccitech, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Barinthus Biotherapeutics

General Information

Discover More

About Barinthus Biotherapeutics

Services & Products

Target Customers

Funding Rounds & Investors (7)

Latest News

Barinthus Biotherapeutics Alternatives & Competitors

FAQ About Barinthus Biotherapeutics